Diplomat named distributor of newly approved Nityr

FLINT, Mich. — Diplomat Pharmacy will be exclusively dispensing Cycle Pharmaceuticals’ Nityr (nitisinone) tablets, the company announced Thursday. The Food and Drug Administration approved Nityr on Aug. 1 to treat the rare disease hereditary tyrosinemia Type 1, or HT-1, in combination with dietary restriction of tyrosine and phenylalanine.

“At Diplomat, our care team works vigorously to ensure our patients receive innovative therapy solutions while providing the high-touch care they deserve," Diplomat president Paul Urick said. “As the sole distributor, we are excited to offer a new treatment option for patients seeking a more convenient therapy and in need of support. Cycle Pharmaceuticals has interpreted the modern health needs of HT-1 patients and caregivers by successfully developing a new treatment to improve their quality of life.”

While there are currently capsules and oral suspensions of nitisinone available, Nityr tablets don’t require refrigeration and it also is available for infants or patients with difficulty swallowing through an oral syringe. The drug is available in 2-, 5- and 10-mg dosage strengths.

“Nityr is the first milestone in the long-term engagement of Cycle Pharmaceuticals with the HT-1 community,” Cycle Pharmaceuticals CEO Antonio Benedetti said when the drug was approved. “ We look forward to working with physicians, caregivers and the patient community to help HT-1 patients benefit from the developments that Nityr brings.”